sgbH Antibody

What is SHBG and why are antibodies against it important in research?

SHBG (Sex Hormone-Binding Globulin) is a plasma glycoprotein that binds to sex hormones, particularly testosterone and estradiol, regulating their bioavailability. Antibodies against SHBG are critical research tools that enable quantification of SHBG levels in plasma and serum, which directly impacts the assessment of hormone activity in various physiological and pathological conditions. The development of specific monoclonal antibodies has significantly advanced the field by allowing for more precise, reproducible measurements compared to earlier techniques. These antibodies recognize specific antigenic determinants on the SHBG protein, ranging from the Leu30-His402 region to other structural epitopes, enabling researchers to design immunoassays with high specificity and sensitivity .

How do monoclonal SHBG antibodies differ from polyclonal antibodies in research applications?

Monoclonal SHBG antibodies offer significant advantages over polyclonal antibodies in research settings, including enhanced specificity, reproducibility, and standardization. Monoclonal antibodies recognize single epitopes on the SHBG molecule, while polyclonal antibodies bind to multiple antigenic determinants. Research has demonstrated that monoclonal antibody-based ELISAs show excellent performance characteristics with faster processing times (same-day results versus two days for polyclonal antibody assays) and are unaffected by the presence of added testosterone or estradiol that might interfere with measurements . Additionally, monoclonal antibodies can be produced consistently in cell culture or ascites fluid and purified to apparent homogeneity through methods such as protein A affinity chromatography, ensuring batch-to-batch consistency essential for longitudinal studies .

What are the major types of SHBG antibodies characterized in research?

Research has characterized several distinct monoclonal antibodies against SHBG with varying properties and applications. For instance, one study described four monoclonal antibodies, with three recognizing different antigenic determinants on SHBG . Another study detailed the S1B5 hybridoma cell line that produces an IgG2α immunoglobulin with exceptionally high affinity (Kd 0.38 × 10⁻¹¹ M) for SHBG . Commercial antibodies like clone #336729 target specific regions (Leu30-His402) of the SHBG protein (Accession # P04278) . These antibodies vary in their utility for different applications—some are optimized for ELISA development as capture or detection antibodies, while others perform well in Western blotting, recognizing distinctive bands at 48 kDa (major) and 46 kDa (minor) in human plasma .

How can SHBG antibodies be effectively employed in ELISA development?

SHBG antibodies can be strategically paired to develop sensitive and specific sandwich ELISA systems for quantifying SHBG in biological samples. The optimal approach involves using two monoclonal antibodies that recognize different epitopes on the SHBG molecule. For example, a capture antibody (such as MAB26561) can be coated onto a microplate to immobilize SHBG from samples, followed by detection using a biotinylated detection antibody (such as MAB26562) . This sandwich configuration can be visualized using streptavidin-HRP and appropriate substrate solutions. Research has demonstrated that such systems can achieve same-day results compared to traditional two-day assays . For assay validation, researchers should perform dilution linearity tests using recombinant human SHBG protein serially diluted two-fold to establish standard curves and determine the dynamic range and sensitivity of the assay .

What methodological considerations are important when using SHBG antibodies in Western blotting?

When employing SHBG antibodies for Western blotting, researchers should consider several critical methodological factors for optimal results. Select antibodies specifically validated for Western blotting applications, as not all SHBG antibodies perform equally in this technique. Research has identified that specific monoclonal antibodies can recognize distinct SHBG bands in human plasma—primarily a major 48 kDa band and a minor 46 kDa component . Importantly, researchers should note that carbohydrate residues do not form part of the antigenic determinants for certain antibodies, though one study demonstrated increased signal following removal of N-linked oligosaccharides for a specific antibody . When optimizing Western blotting protocols, researchers should determine appropriate antibody dilutions empirically for each application and consider using protein A-purified antibodies for improved specificity and reduced background .

What are the cross-reactivity profiles of SHBG antibodies across species?

SHBG antibodies exhibit specific cross-reactivity patterns that researchers must consider when designing studies involving different species. Research has demonstrated that certain monoclonal antibodies, such as those from the S1B5 hybridoma cell line, show competitive, superimposable displacement with human, chimpanzee, and gorilla sera at comparable SHBG concentrations, indicating strong cross-reactivity with great apes . Partial cross-reaction has been observed with sera from other Old World primates, while no significant cross-reactivity was detected with New World monkeys or other vertebrate species . This evolutionary restriction in cross-reactivity aligns with the structural conservation of SHBG across closely related primate species. Researchers working with non-human models should validate antibody performance with their specific species of interest rather than assuming cross-reactivity based on phylogenetic relationships .

How should sample collection and preparation be optimized for SHBG antibody-based assays?

Sample collection and preparation protocols significantly impact the reliability of SHBG antibody-based assays. For hormonal studies involving SHBG measurement, timing relative to hormone administration is critical. For individuals on hormone therapies, samples should be collected 12-24 hours after the last dose for oral, topical, and vaginal formulations, 1-2 days after applying patches, and at the midpoint between injections or pellet insertions . Blood spot testing is preferred over saliva testing for patients using sublingual hormones due to direct contamination concerns . Researchers should instruct participants to avoid anti-wrinkle creams for at least 3 days before collection, as these may interfere with assay performance . For menstruating females not on oral contraceptives, sample collection should occur on days 19-21 of the cycle (counting the first day of bleeding as day 1) to standardize hormone fluctuations . Importantly, researchers should postpone sample collection when subjects are ill, as illness can affect hormone levels and potentially compromise SHBG measurements .

What controls and standards are essential for validating SHBG antibody-based assays?

Proper validation of SHBG antibody-based assays requires comprehensive controls and standards. Research indicates that assays using the same reference standard (NIBSC code 95/560 SHBG standard) demonstrate better correlation, with slopes indistinguishable from unity when compared . Essential positive controls should include serum samples with known SHBG concentrations spanning the expected clinical range (from just detectable to >100 nM) . Negative controls should include samples from species known not to cross-react with the antibody, such as samples from New World monkeys when using antibodies like those from the S1B5 hybridoma line . Assay validation should include assessment of linearity, precision, accuracy, and the limits of detection and quantification. Serial dilutions of recombinant human SHBG protein can establish standard curves for quantification purposes . Interference testing should include evaluation of potential cross-reactants such as testosterone and estradiol, which have been shown not to affect specific monoclonal antibody-based ELISAs .

How do SHBG levels correlate with metabolic and endocrine parameters in research studies?

Research has revealed complex relationships between SHBG levels and various metabolic and endocrine parameters. Univariate regression analyses consistently show significant positive correlations between SHBG and age, adiponectin, total testosterone, and dihydrotestosterone (DHT) across multiple assay platforms . Conversely, insulin demonstrates a strong negative correlation with SHBG (P ≤ 0.00076), supporting the hypothesis that insulin may regulate SHBG production . Multivariate models indicate that age, insulin, and adiponectin together explain one-third to one-half of the intersubject variance in SHBG concentrations (R² values ranging from 0.381 to 0.525) . Interestingly, platform-specific correlations exist—SHBG measured by immunoassays correlates with albumin levels, while mass spectrometry-derived SHBG values show associations with free testosterone . These findings underscore the importance of considering the assay platform when interpreting SHBG correlations with physiological parameters in research studies .

What is the relationship between SHBG levels and chronic kidney disease (CKD) risk?

Research has uncovered a nonlinear relationship between SHBG levels and chronic kidney disease (CKD) risk, with significant implications for using SHBG as a potential biomarker in kidney research. A comprehensive study using national representative population data demonstrated that SHBG levels are associated with CKD risk (OR: 1.24; 95% CI: 1.11–1.38), indicating a 24% higher risk of CKD for elevated SHBG levels after adjusting for multiple confounding factors . Notably, restricted cubic spline models revealed a nonlinear association with a threshold effect—when SHBG levels were below 46.1 nmol/L, no significant association with CKD risk was observed (OR = 0.656, 95% CI: 0.408–1.053, P = 0.081), but a significant positive association emerged when SHBG levels exceeded this threshold (OR = 1.377, 95% CI: 1.202–1.557, P < 0.001) . This nonlinearity may help explain contradictory findings in previous studies and suggests that researchers should consider threshold effects rather than simple linear relationships when investigating SHBG's role in kidney function .

How should researchers address inconsistencies in SHBG-related findings across different studies?

Researchers must carefully consider several methodological factors when addressing inconsistencies in SHBG-related findings across studies. First, assay platform differences significantly contribute to non-uniformities in results—studies using different standards or methodologies may yield systematically different SHBG measurements, particularly at higher concentrations (>100 nM) . Second, population characteristics matter substantially—research has shown different SHBG associations in general populations versus specific cohorts with metabolic diseases; factors such as age distribution, gender ratio, and racial composition can significantly influence outcomes . Third, statistical approach is critical—linear models may miss important nonlinear relationships, as demonstrated by the threshold effect at 46.1 nmol/L in SHBG-CKD associations . Fourth, adjustment for confounders varies across studies—comprehensive models should account for age, gender, race, education, BMI, sex hormones, lipid profiles, renal function markers, lifestyle factors, and comorbidities to isolate true SHBG relationships . Finally, researchers should consider bidirectional relationships—while some studies suggest SHBG affects disease risk, others using genetic prediction models indicate that elevated SHBG levels may be associated with reduced CKD risk, suggesting complex causal pathways requiring careful interpretation .

How can researchers optimize SHBG antibody pairs for developing highly sensitive sandwich ELISAs?

Developing highly sensitive sandwich ELISAs for SHBG requires strategic antibody pair selection and methodical optimization. Researchers should select antibodies that recognize distinct, non-overlapping epitopes on the SHBG molecule to maximize capture and detection efficiency. For instance, the combination of a capture antibody like MAB26561 with a detection antibody such as MAB26562 (clone #336729) has been validated for this purpose . Biotinylation of the detection antibody followed by streptavidin-HRP visualization enhances signal amplification and improves sensitivity . Optimization should include titration of both antibodies to determine optimal concentrations, evaluation of different blocking reagents to minimize background, and assessment of sample dilution requirements to ensure measurements fall within the linear range of the assay. Researchers should validate their assay against established methods—studies have shown that optimized monoclonal antibody-based ELISAs correlate well with both polyclonal antibody ELISAs and dihydrotestosterone ligand-binding assays while offering advantages in processing time and resistance to interference from added testosterone or estradiol .

What techniques can be employed to characterize the epitope specificity of SHBG antibodies?

Characterizing epitope specificity of SHBG antibodies requires a multi-technique approach to generate comprehensive binding profiles. Competitive binding assays can determine whether different antibodies recognize overlapping or distinct epitopes—research has identified three out of four monoclonal antibodies that recognize different antigenic determinants on SHBG . Epitope mapping through peptide arrays or hydrogen-deuterium exchange mass spectrometry can pinpoint specific binding regions, such as the Leu30-His402 region targeted by clone #336729 . Glycosylation influence can be assessed through enzymatic deglycosylation experiments—studies have demonstrated that carbohydrate residues do not form part of the antigenic determinants for certain SHBG antibodies, although removal of N-linked oligosaccharides increased signal for one antibody . Cross-species reactivity testing provides evolutionary insights into conserved epitopes—the S1B5 hybridoma antibody shows strong cross-reactivity with great apes but diminishing reactivity with more distantly related primates . Additionally, isoelectric focusing can reveal characteristic binding patterns, such as the series of bands at pH 8.5-9 observed with certain anti-SHBG antibodies .